Reply to the letter by Gaetano Loscocco, Secondary hemophagocytic lymphohistiocytosis, HScore and COVID-19
Tóm tắt
Từ khóa
Tài liệu tham khảo
Takami A. Possible role of low-dose etoposide therapy for hemophagocytic lymphohistiocytosis by COVID-19. Int J Hematol. 2020. https://doi.org/10.1007/s12185-020-02888-9.
Mehta P, McAuley DF, Brown M, Sanchez E, Tattersall RS, Manson JJ, et al. COVID-19: consider cytokine storm syndromes and immunosuppression. Lancet. 2020;395(10229):1033–4. https://doi.org/10.1016/S0140-6736(20)30628-0.
Prilutskiy A, Kritselis M, Shevtsov A, Yambayev I, Vadlamudi C, Zhao Q, et al. SARS-CoV-2 infection associated hemophagocytic lymphohistiocytosis: an autopsy series with clinical and laboratory correlation. medRxiv. 2020. https://doi.org/10.1101/2020.05.07.20094888.
Faguer S, Del Bello A, Abravanel F, Nicolau-Travers ML, Kamar N. Tocilizumab for hemophagocytic syndrome in a kidney transplant recipient with COVID-19. Ann Intern Med. 2020. https://doi.org/10.7326/L20-0419.
Dimopoulos G, de Mast Q, Markou N, Theodorakopoulou M, Komnos A, Mouktaroudi M, et al. Favorable anakinra responses in severe Covid-19 patients with secondary hemophagocytic lymphohistiocytosis. Cell Host Microbe. 2020. https://doi.org/10.1016/j.chom.2020.05.007.
Ye Q, Wang B, Mao J. The pathogenesis and treatment of the ‘Cytokine Storm’ in COVID-19. J Infect. 2020;80(6):607–13. https://doi.org/10.1016/j.jinf.2020.03.037.